Background: Smoking is a major risk factor for a range of diseases, and quitting smoking provides
Introduction
Tobacco use is the biggest cause of preventable morbidity and mortality in the UK 1 . The diseases it causes or exacerbates include cancer, heart disease, lung disease, stroke, peripheral vascular disease, diabetes, infection, dementia and macular degeneration 2 . In addition to premature mortality, these diseases cause disability that contributes to social and economic disadvantage 3 , loss of productivity 4 , and dependence on family or socially-funded carers. The financial cost to society of these and other effects of tobacco smoking are estimated to be in excess of £13 billion per annum 5 . This individual and societal burden of disease can be prevented for future generations by preventing the uptake of smoking among young people 6 . However, reducing this burden in the more immediate future is dependent upon helping as many current smokers as possible to quit smoking. This is particularly relevant to smokers who have already developed a disease caused or exacerbated by smoking, since stopping smoking can arrest or in some cases reverse the progression of their disease 7 . It therefore follows that smoking cessation interventions or reference to published smoking cessation guidelines should be a key component of the clinical management of these diseases, and hence also of published guidelines or their updates on their clinical management.
We have therefore systematically examined clinical management guidelines produced by professional societies and governmental agencies in the UK and Europe for a range of smokingrelated diseases, to assess the extent to which smoking cessation interventions are prioritised within them.
Methods
We carried out a series of systematic reviews of clinical guidelines and clinical recommendations published since 2000 and produced under the auspices of a relevant UK national or European transnational medical speciality association, professional society or government agency, and relating to a range of diseases caused or exacerbated by smoking comprising cancer of the lip, oral cavity and pharynx, oesophagus, lung, stomach, pancreas, kidney, pelvis or bladder; cardiovascular disease (including ischaemic heart disease, angina, myocardial infarction, aortic aneurysms); cerebrovascular disease (including stroke, transient ischaemic attack, brain aneurysm); or respiratory disease (pneumonia and COPD). We excluded guidelines produced by and for individual European countries outside the UK.
A series of search strategies were developed for two electronic databases (Medline and EMBASE) using recognised search filters for identifying clinical guidelines as developed by the Guideline Resource Centre 8 for each disease. Disease specific terms were developed using the relevant search terms as developed by Cochrane Review Groups. Searches were typically conducted to the end of 2013. We additionally searched the National Library for Health (NLH) Guidelines Finder, the TRIP database, and the International Guideline Library.
We then searched individual guideline documents to establish whether i) smoking was identified as a risk factor or major cause of disease; ii) smoking cessation interventions were recommended in disease management; and iii) whether there was reference or a link to specific smoking cessation guidelines (for example, the National Institute for Health and Care Excellence guidelines for various diseases provide reference to smoking cessation guidelines rather than include specific treatment recommendations) or recommendations on evidence-based treatments for smoking cessation, including behavioural support and pharmacotherapy, or referral to a stop smoking service.
The titles, abstracts, and full texts were screened by two reviewers independently to select eligible guidelines using previously piloted checklist forms. Disagreements were resolved through discussion with a third reviewer. One reviewer extracted data relating to agency responsible for developing/issuing guidelines, country of origin, year of publication, status of clinical guidelines (new or updated), and level of development (UK/European) using piloted data extraction form. Simple descriptive summary statistics are used to report the presence of the smoking cessation advice within the guidelines; summaries of these studies are also reported.
Results
Our searches identified 141 eligible clinical guidelines, of which 37 were produced in the UK and 104
by a European medical speciality association, relevant professional society or government agency.
Two of the guidelines were included more than once as they had distinct sections on more than one eligible cancer under investigation 9, 10 , thus a total of 144 guidelines were included in the review. Of the 144, 86 (60%) referred to smoking as a risk factor for the development of the disease; 57 (40%) provided a statement regarding smoking cessation; and 28 (19%) made reference to specific treatments for smoking cessation or to a smoking cessation guideline ( . Both mentioned smoking as a risk factor for head and neck cancer and highlighted the importance of smoking cessation, and provided details of specific treatments or else referred to a guideline for smoking cessation.
Oesophageal cancer
From 1,884 titles identified, 22 were selected based on title and abstract and eight included after full text screening 9, 10, [13] [14] [15] [16] [17] [18] . Four guidelines were from the UK 9, 10, 13, 15 and four were European 14, 16-18 . Only four guidelines (50%), three UK and one European, mentioned smoking as a risk factor for oesophageal cancer. All three of these UK guidelines discussed the benefits of smoking cessation 9, 13, 15 , but only one provided a link to smoking cessation management guidelines 9 . 
Lung cancer

Gastric cancer
From 7,259 titles identified from the searches, 34 were selected based on title and abstract and 16
after full text screening 9, 10, [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . Ten of the included guidelines (63%) referred to smoking as a risk factor for gastric cancer 9, 10, 45-47, 49, 51, 53, 55, 57 but only four (25%; all UK-based) recommended that smoking cessation should be advised 9, 10, 45, 47 , and only one of these provided a link to smoking cessation management guidelines 9 .
Pancreatic cancer
From 1,636 titles identified from the searches, 29 were selected on title and abstract and 14 after full text screening 9, [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] . Only three (21%; two UK 9, 59 and one European
71
) of these 14 guidelines referred to smoking as a risk factor for pancreatic cancer, and one referred to smoking cessation and provided a link to smoking cessation management guidelines 9 .
Kidney, pelvis and bladder cancer
From 4,411 titles identified from the searches, 67 were selected based on titles and abstracts and 35
after full text screening . Nineteen (54%) of these reported that smoking increased the risk of , but only one referred to smoking cessation 76 and none included any link or recommendation on smoking cessation therapy.
Cerebrovascular disease
From 12,414 titles identified, 78 were potentially eligible based on title and abstract and 11 after full text screening [107] [108] [109] [110] [111] [112] [113] [114] [115] [116] [117] . Five (36%) of these mentioned smoking as a risk factor for cerebrovascular disease 110, 111, 116 ; 6 (55%; 3 UK and 3 European) recommended smoking cessation 110, 111, 115, 116 ; and none referred to specific treatments or referenced any smoking cessation guidelines.
Cardiovascular disease
From 13,351 titles identified in the searches, 135 were selected based on titles and abstracts and 21
after full text screening . ; and reduces the risk of lung infections and of asthma exacerbation 154 . In lung cancer, smoking cessation at diagnosis in early stage disease is associated with significantly improved survival 155 . In cardiovascular disease, smoking cessation reduces the risk of recurrence by around 50% over the longer term, and in cerebrovascular disease by around 15% [156] [157] [158] [159] [160] . Smoking cessation should therefore be a high priority in managing these diseases, and it would therefore be reasonable to expect definitive management guidelines to recognize this. Our finding that even in respiratory and cardiovascular disease, reference to appropriate smoking cessation guidance or provision of specific advice was far from universal indicates that smoking cessation is not receiving the attention it merits in the management of these conditions.
For the less common cancers caused by smoking, such as cancer of the oesophagus, pancreas and bladder, inclusion of cessation guidance was generally (with the exception of guidance on cancer of the lip, oral cavity or pharynx), even less common. There is evidence that smoking cessation improves life expectancy in early stage lung cancer, cardiovascular and respiratory disease 154, 155 ; and smoking cessation is likely to have a significant impact in also preventing intercurrent infections 161, 162 , promoting wound healing [163] [164] [165] , and other benefits to the management of these conditions. It is therefore surprising that smoking cessation is afforded so little priority in the management of these less common cancers. The impact of this omission is likely to be inadequate treatment of tobacco addiction, with the consequence of an excess of several hundred thousand preventable deaths and significant morbidity.
Why is this omission so common? There are many potential plausible causes. The authors of these guidelines may be experts in specific disease but may not be so knowledgeable in understanding the links between tobacco use and disease progression or the benefits of smoking cessation in established disease 151, 155, [166] [167] [168] . Authors may also underestimate the strength of tobacco addiction 169 , the difficulty overcoming this addiction 170 or may lack the knowledge of the most effective methods to achieve smoking cessation 171 . In addition, authors may be influenced by other barriers that effect health professionals discussing smoking cessation with patients such as time, knowledge, perceived lack of efficacy or their own use of tobacco [172] [173] [174] . A less benign reason for our findings may be the influence of device manufacturers and pharmaceutical companies on guideline production 175 , since disease prevention runs contrary to their commercial interest. Finally, it may be that authors of guidelines are focusing on novel procedures or pharmacotherapy and weight these recommendations higher than more 'conservative' measures despite the effectiveness of the latter 176 .
We used robust search strategies and screening methods to identify and assess the eligibility of the clinical guidelines included in the review; therefore it is unlikely that any guidelines we did not identify would have a significant impact on our findings. The indexing of clinical guidelines is still being developed; therefore our search strategies were very sensitive and identified many articles that were not relevant. Some of the included guidelines were in the form of a very short consensus document or a shortened updated guideline; therefore, due to the restrictions on the length of the documents it is likely that smoking or smoking cessation may not have been mentioned. However, if the disease is caused by smoking or smoking contributes to its development and smoking cessation could reduce risk of the disease or death it should be mentioned in the short versions or updates of guidelines, for example, by providing a reference to existing guidelines as often observed in NICE guidelines. Our finding that major guidelines on cardiovascular disease, cancer and respiratory diseases across Europe neglect smoking prevention is likely to reflect low levels of intervention to prevent smoking among people with smoking-related disease, and a consequent failure to avoid significant morbidity and mortality.
Conclusion
A plethora of guidelines is produced each year, by a variety of institutions and professional societies to disseminate research findings, best practice and to reduce variation in care. Their quality is variable, and dissemination and impact of guidelines often poor 177 . We hope that by drawing attention to this deficiency in the inclusion of smoking cessation we can improve this and that this will be reflected in changes in clinical practice. For the general standard of smoking cessation advice and intervention to be raised, governmental and peer review of practice standards, government health policy driving change, smoke-free legislation, commissioning of services and anti-tobacco advocacy groups will be needed. 
